Rational selection of the monoclonal α-synuclein antibody amlenetug (Lu AF82422) for the treatment of α-synucleinopathies - npj Parkinson's Disease npj Parkinson's Disease - Rational selection of the monoclonal α-synuclein antibody amlenetug (Lu AF82422) for the treatment of α-synucleinopathies

This highlights the development of a promising antibody therapy, #Amlenetug, designed to target toxic forms of Alpha-Synuclein

Our ASyn and ASyn 1-60 were used to characterize different conformations of the protein and select an antibody with the right binding properties

t.ly/FbB2w

#Research

Lundbeck Reveals Pioneering Trial Design for Amlenetug at 2025 Movement Disorders Congress At the 2025 Congress, Lundbeck will present its innovative Phase 3 trial for Amlenetug aimed at treating Multiple System Atrophy, addressing significant patient needs.

Lundbeck Reveals Pioneering Trial Design for Amlenetug at 2025 Movement Disorders Congress #USA #Honolulu #Lundbeck #MSA #Amlenetug

Lundbeck to Present Phase 3 MASCOT Trial Design for MSA at International Congress in 2025 Lundbeck will reveal the innovative Phase 3 MASCOT trial design for amlenetug in treating Multiple System Atrophy at the upcoming congress.

Lundbeck to Present Phase 3 MASCOT Trial Design for MSA at International Congress in 2025 #Denmark #Lundbeck #Valby #Amlenetug #mascot

Lundbeck Unveils Promising MSA Treatment Data at International Congress in Boston At the International MSA Congress in Boston, Lundbeck shares critical insights from the AMULET trial and MSA progression data to aid future treatments.

Lundbeck Unveils Promising MSA Treatment Data at International Congress in Boston #USA #Boston #Lundbeck #MSA #Amlenetug

Lundbeck's Promising New Drug Amlenetug Receives Orphan Drug Designation in Japan The Japanese MHLW has granted Orphan Drug Designation to amlenetug, Lundbeck's investigational drug for Multiple System Atrophy, highlighting its potential as a treatment option.

Lundbeck's Promising New Drug Amlenetug Receives Orphan Drug Designation in Japan #Japan #Tokyo #Lundbeck #MSA #Amlenetug

Lundbeck's Amlenetug Receives Orphan Drug Designation in Japan, Aiming to Combat MSA Lundbeck's amlenetug has been granted Orphan Drug Designation in Japan, marking a significant step in the treatment for Multiple System Atrophy.

Lundbeck's Amlenetug Receives Orphan Drug Designation in Japan, Aiming to Combat MSA #Japan #Tokyo #Lundbeck #MSA #Amlenetug

Lundbeck's Amlenetug Achieves Fast Track Status for Treating Rare Disease Multiple System Atrophy H. Lundbeck A/S's investigational treatment amlenetug has received Fast Track designation from the FDA, aiming to treat Multiple System Atrophy, a rare neurodegenerative condition.

Lundbeck's Amlenetug Achieves Fast Track Status for Treating Rare Disease Multiple System Atrophy #Denmark #Lundbeck #MSA #Valby #Amlenetug